vimarsana.com
Home
Live Updates
Centessa Pharmaceuticals to Present Additional 52-Weeks of C
Centessa Pharmaceuticals to Present Additional 52-Weeks of C
Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)
BOSTON & LONDON, Feb. 09, 2024 -- Centessa Pharmaceuticals plc announced that data from an additional 52-weeks of continuous treatment from the third year of the ongoing Phase 2a study of...
Related Keywords
Israel ,
Germany ,
Russia ,
Ukraine ,
Oberland ,
Thün ,
United States ,
Boston ,
Massachusetts ,
Palestinian ,
Israeli ,
American ,
Trevor Baglin ,
Kristenk Sheppard ,
Centessa Pharmaceuticals ,
Drug Administration ,
American Society Of Hematology ,
Exchange Commission ,
European Association For Haemophilia ,
Nasdaq ,
Hemophilia At Centessa Pharmaceuticals ,
Annual Congress ,
European Association ,
Allied Disorders ,
American Society ,
Saurabh Saha ,
Chief Executive Officer ,
Global Head ,
Clinical Trial ,
Fast Track ,
Accelerated Approval ,
Priority Review ,
Rolling Review ,
Annual Report ,
Quarterly Reports ,
Investor Relations ,
Markets ,